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Another Stitch in the Patchwork*John A. Savino III, MD, Jonathan L. Halperin, MDSEE PAGE 1339T he frequency with which clinicians encounterpatients with nonvalvular atrial ﬁbrillation(AF) and its association with ischemic stroke
make estimation of the risk borne by individuals a
daily issue in contemporary cardiology practice across
the globe. In the balance lies the decision to employ
long-term anticoagulation therapy with its attendant
risk of severe bleeding. A variety of clinical risk scores
are available to guide this decision, most prominently
the CHA2DS2-VASc score, which cumulates the widely
accepted, if unequally validated, clinical risk factors:
heart failure (or impaired left ventricular function),
hypertension, age, prior stroke (or transient ischemic
attack or systemic thromboembolism), atherosclerotic
vascular disease (as manifested by myocardial infarc-
tion, peripheral artery disease, or morphologically
complex aortic atheroma), and female sex (1). Other
scores recognize impaired renal function or other
variables (2), and some emerging risk stratiﬁcation
approaches incorporate biomarkers, imaging of the
morphology or ﬂow properties of the left atrial
appendage, and other considerations into the anti-
coagulation decision.
For over 20 years, however, patient age has been
recognized as a consistent independent risk factor
for stroke that carries an incremental relative risk of
about 1.5 (95% conﬁdence interval: 1.3 to 1.7) per
decade (3,4). Although stroke prevention trials have*Editorials published in the Journal of the American College of Cardiology
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stage, much of the data from which clinical risk
stratiﬁcation schemes derive were acquired in West-
ern, mainly Caucasian patient cohorts. In this issue of
the Journal, Chao et al. (5) report on the differential
risk of ischemic stroke in patients of Taiwanese origin
with AF stratiﬁed according to the CHA2DS2-VASccriteria as at relatively low risk (CHA2DS2-VASc of 0 for
men, 1 for women) (5). On the basis of approximately
9,400 men and 6,400 women with AF in a national
registry, the main ﬁnding is that the risk of stroke in
patients with AF but no CHA2DS2-VASc risk factors
other than sex is higher among Taiwanese adults than
previously recognized, with the important implication
that stroke risk is subject to variation by ethnicity.
Heretofore, ethnic differences have not been specif-
ically incorporated into clinical practice guidelines,
due mainly to paucity of data.
Several recent studies have reported wide varia-
tions in stroke risk among cohorts with low CHA2DS2-
VASc risk scores. Stroke rates in a Danish cohort (6)
(0.66%/year for men with a CHA2DS2-VASc score of
0 and 0.82%/year for women with scores of 1) were
substantially higher than in a similar Swedish cohort,
where rates were about 0.2%/year (7). Low rates have
also been reported from the United States (2),
whereas another analysis found the Taiwanese pop-
ulation at higher risk (8). The authors point out
consistently increased risks of ischemic stroke in
the Asian cohorts of RE-LY (Randomized Evaluation
of Long-Term Anti-coagulation Therapy), ROCKET-
AF (Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation), and ARISTOTLE (Apixaban for
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1349Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation), and the new data they
provide suggests that a lower age threshold may be
appropriate for selecting patients of Taiwanese
ethnicity for anticoagulation.
It is important to bear in mind, though, that opti-
mum treatment cannot be determined without pro-
spective studies. Indeed, even assuming that the risk
of bleeding is lower among younger patients, it is
uncertain whether the cut-point should bet set at 50,
55, or 60 years, or some intermediate age. We should
also be cautious in extrapolating the ﬁndings to other
Asian populations. And although ethnicity seems
pertinent, a host of clinical factors must be consid-
ered in the decision to employ long-term anti-
coagulation, not only those contributing to the
thromboembolic and hemorrhagic risks, but also dif-
ferences in response to the array of anticoagulant
drugs that are now available, some of which are
inﬂuenced by genetics and ethnicity (9,10).
Even more fundamental is the lack of information
about the role of AF in the interplay between age and
stroke risk. Does the risk of stroke among otherwise
low-risk Taiwanese individuals without AF differ
from people of other ethnic backgrounds? Evidence is
accumulating that the CHA2DS2-VASc score, as well asother risk stratiﬁcation schemes that are useful for
patients with AF, can be applied with similar predic-
tive value to assess the risk of stroke in patients
without AF (11,12). Furthermore, speciﬁc genetic
markers may be closely linked to stroke risk (13).
For patients with AF in whom the decision to
employ anticoagulant medication hovers near the
margin of risk and beneﬁt, physicians must consider
more than age and other risk factors for thrombo-
embolism and bleeding. We must engage in a dia-
logue that acknowledges ethnicity, cultural and
personal values, preferences, and social factors to
ensure a balanced, comprehensive assessment that
enhances adherence, safety, and clinical outcomes.
Ethnicity is another piece of the puzzle, but exactly
how to integrate this variable into clinical care will
require innovative approaches to clinical research
utilizing techniques of network biology to identify
pathways or gene sets linked to the pathogenesis of
atrial ﬁbrillation and thromboembolism.
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